XenoPort, Inc.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1999-01-01
- Employees
- 251
- Market Cap
- -
- Website
- http://xenoport.com
Clinical Trials
26
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (26 trials with phase data)• Click on a phase to view related trials
An Extension Study to Evaluate the Efficacy and Safety of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS
- First Posted Date
- 2015-12-17
- Last Posted Date
- 2021-06-09
- Lead Sponsor
- XenoPort, Inc.
- Target Recruit Count
- 144
- Registration Number
- NCT02633683
- Locations
- 🇺🇸
Stanford Sleep Medicine Center, Redwood City, California, United States
🇺🇸Pacific Research Network, San Diego, California, United States
🇺🇸NW FL Clinical Research Group, Gulf Breeze, Florida, United States
A PK and Safety Evaluation of HORIZANT (Gabapentin Enacarbil) in Adolescents With Moderate-to-Severe Primary RLS
- First Posted Date
- 2015-12-17
- Last Posted Date
- 2021-04-12
- Lead Sponsor
- XenoPort, Inc.
- Registration Number
- NCT02633657
- Locations
- 🇺🇸
Stanford Sleep Medicine Center, Redwood City, California, United States
🇺🇸Pacific Research Network, Saint Louis, Missouri, United States
🇺🇸SleepMed of South Carolina; SleepMed, Inc., Columbia, South Carolina, United States
An Efficacy and Safety Evaluation of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS
- First Posted Date
- 2015-09-25
- Last Posted Date
- 2021-06-09
- Lead Sponsor
- XenoPort, Inc.
- Target Recruit Count
- 132
- Registration Number
- NCT02560766
- Locations
- 🇺🇸
Stanford Sleep Medicine Center, Redwood City, California, United States
🇺🇸NW FL Clinical Research Group, Gulf Breeze, Florida, United States
🇺🇸Orlando Pediatric Pulmonary and Sleep, Winter Park, Florida, United States
Gabapentin Enacarbil (GSK1838262) Adult Restless Leg Syndrome (RLS) Post Marketing Commitment Study
- Conditions
- Restless Legs Syndrome
- Interventions
- Drug: GSK1838262 300 mgDrug: GSK1838262 600 mgDrug: GSK1838262 450 mgDrug: GSK1838262 Placebo match
- First Posted Date
- 2012-08-20
- Last Posted Date
- 2021-05-24
- Lead Sponsor
- XenoPort, Inc.
- Target Recruit Count
- 501
- Registration Number
- NCT01668667
- Locations
- 🇺🇸
GSK Investigational Site, Charlottesville, Virginia, United States
A Study to Evaluate the Effect of Gabapentin on Cardiac Repolarization in Healthy Volunteers
- Conditions
- Restless Legs Syndrome
- Interventions
- First Posted Date
- 2012-01-24
- Last Posted Date
- 2021-04-12
- Lead Sponsor
- XenoPort, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT01516372
- Locations
- 🇺🇸
GSK Investigational Site, Austin, Texas, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- Next